Testosterone pellets: what TikTok gets right and wrong
Quick answer
Testosterone pellets deliver subcutaneous continuous-release testosterone, typically lasting 3-6 months, with less provider control over dose adjustment compared to injectable or topical formulations. Published data supports elevated erythrocytosis risk with pellets relative to other delivery methods, and extrusion is a documented complication, though rates in the literature are far below the 50% figure cited in this video. Patients transitioning off pellets to injectable testosterone may experience a symptomatic hypogonadal window as pellets deplete, which warrants active monitoring rather than passive waiting.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @trt__np actually say?
The creator, presenting as a nurse practitioner, came out swinging against testosterone pellets in response to a patient who had just booked an insertion appointment. The core argument: pellets give you zero dosing control, they "spike your red blood cells," they "plummet your SHBG," they fall out in the shower about half the time, and patients can be stuck riding out unpredictable hormone levels for six to nine months. The NP also claimed they have "never seen good results on testosterone pellets for men, ever" and that pellets force patients to wait out a hormonal crash before switching to injections. They finished with a pitch for their own practice.
To be fair, this is clinical opinion grounded in real patient experience, not fringe internet advice. Some of the concerns raised here have genuine support in the literature. But several specific claims are overstated, one statistic appears fabricated, and the absolutism throughout does a disservice to patients trying to make informed decisions.
Does the science back this up?
Partly. The concern about elevated hematocrit with pellets is well-documented. A study by Pastuszak et al. (2015, Journal of Sexual Medicine) found that pellet-dosed men showed significantly higher rates of polycythemia compared to men on topical testosterone. Elevated red blood cell production is a real, monitored risk across all testosterone delivery methods, but pellets do appear to produce more pronounced erythrocytosis in some patients.
The SHBG suppression claim also has a basis in reality. Because pellets deliver a continuous, relatively high-dose testosterone load, SHBG suppression can be more pronounced than with weekly or twice-weekly injections. Lower SHBG means more free testosterone, which is not inherently bad, but it does complicate interpretation of standard lab panels.
On extrusion, a systematic review by Fears et al. (2023, Sexual Medicine Reviews) documented extrusion rates ranging from roughly 1% to 9% depending on pellet type, insertion site, and activity level. The NP's claim that "50% of the time guys... will bore out of their body" is not supported by published data. That number is off by a significant margin and should not be repeated as fact.
What did they get wrong (or right)?
The extrusion rate claim is the clearest factual error here. A 50% extrusion rate is not what the literature shows. The actual published range sits well under 10% in most studies. Repeating that figure to a patient who just booked an appointment is the kind of thing that erodes trust in clinical content broadly.
The "no control" argument is more nuanced than presented. Pellet dosing protocols have become more refined. Clinicians can adjust pellet count and pellet size at insertion based on weight, baseline testosterone, and symptom burden. That is not the same as the day-to-day titration you get with injections, but calling it zero control misrepresents how experienced pellet providers actually work.
Where the NP deserves credit: the point about getting "stuck" is legitimate. Unlike injections or gels, you cannot simply stop a pellet. If a patient develops polycythemia, a hematocrit above 54%, or feels miserable on too-high levels, there is no easy off switch. That is a real clinical limitation, and it is a reasonable basis for preference toward injectable or topical delivery in patients who may need frequent dose adjustments.
What should you actually know?
No testosterone delivery method is universally best. Pellets, injections, gels, and patches each carry distinct pharmacokinetic profiles, side effect risks, and lifestyle trade-offs. A 2021 review by Ramasamy et al. in Therapeutic Advances in Urology compared delivery methods and found that patient satisfaction data does not cleanly favor one approach. Some men do well on pellets. Some do not.
The "crash" concern when transitioning off pellets is real and underappreciated. As pellets deplete, testosterone can drop below baseline before clearing completely. A provider who understands this transition and manages it proactively adds genuine value. The NP's claim to have developed a protocol for this is not implausible, though no peer-reviewed data supports the specific approach described.
If you are considering any form of TRT, the delivery method conversation matters far less than baseline labs, monitoring frequency, and whether your provider will actually respond when something goes wrong. That part of the NP's message, "you call me, I fix it right then and there," reflects a real advantage of titratable delivery systems, even if the surrounding claims were not all accurate.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Testosterone pellets: what TikTok gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Testosterone pellets: what TikTok gets right and wrong should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Testosterone pellets deliver subcutaneous continuous-release testosterone, typically lasting 3-6 months, with less provider control over dose adjustment compared to injectable or topical formulations.
FormBlends verdict
Testosterone pellets deliver subcutaneous continuous-release testosterone, typically lasting 3-6 months, with less provider control over dose adjustment compared to injectable or topical formulations. Published data supports elevated erythrocytosis risk with pellets relative to other delivery methods, and extrusion is a documented complication, though rates in the literature are far below the 50% figure cited in this video. Patients transitioning off pellets to injectable testosterone may experience a symptomatic hypogonadal window as pellets deplete, which warrants active monitoring rather than passive waiting.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Testosterone pellets deliver subcutaneous continuous-release testosterone, typically lasting 3-6 months, with less provider control over dose adjustment compared to injectable or topical formulations. Published data supports elevated erythrocytosis risk with pellets relative to other delivery methods, and extrusion is a documented complication, though rates in the literature are far below the 50% figure cited in this video. Patients transitioning off pellets to injectable testosterone may experience a symptomatic hypogonadal window as pellets deplete, which warrants active monitoring rather than passive waiting.
- Pellet extrusion rates in peer-reviewed studies range from 1% to 9%, not the 50% figure cited in this video (Fears et al., 2023, Sexual Medicine Reviews).
- Pellets do carry a higher polycythemia risk than some other delivery methods. Pastuszak et al. (2015) found elevated hematocrit was more common in pellet-dosed patients compared to topical testosterone users.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Pellet extrusion rates in peer-reviewed studies range from 1% to 9%, not the 50% figure cited in this video (Fears et al., 2023, Sexual Medicine Reviews).
- Pellets do carry a higher polycythemia risk than some other delivery methods. Pastuszak et al. (2015) found elevated hematocrit was more common in pellet-dosed patients compared to topical testosterone users.
- No testosterone delivery method has been shown to produce superior overall patient satisfaction in head-to-head data. Ramasamy et al. (2021, Therapeutic Advances in Urology) found satisfaction varies by individual patient factors.
- The inability to stop or adjust a pellet after insertion is a real clinical limitation, particularly for patients who may develop side effects requiring dose reduction or temporary cessation.
- SHBG suppression from continuous pellet delivery is documented and affects how lab results should be interpreted, but low SHBG alone is not a harm endpoint without accompanying symptoms or cardiovascular risk.
- The transitional period as pellets deplete can produce symptomatic low testosterone. Proactive monitoring during this window is clinically reasonable, regardless of which provider manages it.
- Any TRT decision should be based on baseline labs, symptom burden, lifestyle factors, and a provider's monitoring capacity, not solely on delivery method preference or a single practitioner's clinical opinion.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
trt__np · TikTok creator
18.1K views on this video
Replying to @stuart little #elevatewellnessgroupnj #testosteronepellets
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by trt__np, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.